![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University Chiba, Japan (M.N., R.H., T.H.); and Department of Pharmacy, the University of Tokyo Hospital, the University of Tokyo, Tokyo, Japan (K.I.)
We investigated the intrinsic transport activity of mouse and monkey Mrp2 and compared it with that of rat and dog Mrp2 reported previously. Mrp2 cDNAs were isolated from BALB/c and Macaca fascicularis liver, respectively, and vesicle transport studies were performed using recombinant Mrp2s expressed in insect Sf9 cells. ATP-dependent transport of [3H]leukotriene C4 (LTC4), 3[H]17ß-estradiol 17-(ß-D-glucuronide) (E217ßG), [3H]bromosulfophthalein (BSP), and [3H]cholecystokinin octapeptide (CCK-8) were readily detected for all Mrp2s. A species difference in the intrinsic transport activity was apparent for LTC4 (monkey > mouse, dog > rat) and BSP (rat, dog, monkey > mouse). In addition to the difference in the transport activity, complex kinetic profiles were also evident in CCK-8, where a cooperative transport site was observed. Moreover, the transport of [3H]E217ßG by mouse and monkey Mrp2 was quite different from that of rat and dog Mrp2 in that 1) there was practically only nonsaturable uptake for [3H]E217ßG and 2) 4-methylumbelliferon glucuronide (Mrp2 modulator) showed a concentration-dependent stimulatory effect on the transport of [3H]E217ßG in mouse and monkey Mrp2, whereas rat and dog transport activity was inhibited by the modulator. In conclusion, although the substrate specificity is similar, the intrinsic transport activity differs from one species to another. This is due not only to the difference in the Km and Vmax values, but also the qualitatively different mode of substrate and modulator recognition exhibited by different species.
This article has been cited by other articles:
![]() |
K. Heredi-Szabo, H. Glavinas, E. Kis, D. Mehn, G. Bathori, Z. Veres, L. Kobori, O. von Richter, K. Jemnitz, and P. Krajcsi Multidrug Resistance Protein 2-Mediated Estradiol-17{beta}-D-glucuronide Transport Potentiation: In Vitro-in Vivo Correlation and Species Specificity Drug Metab. Dispos., April 1, 2009; 37(4): 794 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, Y. Zhang, F. Hua, and Y. Lai Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human Drug Metab. Dispos., January 1, 2009; 37(1): 66 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zimmermann, K. van de Wetering, E. van de Steeg, E. Wagenaar, C. Vens, and A. H. Schinkel Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2) Drug Metab. Dispos., April 1, 2008; 36(4): 631 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Heredi-Szabo, E. Kis, E. Molnar, A. Gyorfi, and P. Krajcsi Characterization of 5(6)-Carboxy-2,'7'-Dichlorofluorescein Transport by MRP2 and Utilization of this Substrate as a Fluorescent Surrogate for LTC4 J Biomol Screen, April 1, 2008; 13(4): 295 - 301. [Abstract] [PDF] |
||||
![]() |
E. M. Leslie, G. Ghibellini, K.-i. Nezasa, and K. L.R. Brouwer Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR ) Wistar rats Carcinogenesis, December 1, 2007; 28(12): 2650 - 2656. [Abstract] [Full Text] [PDF] |
||||